{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T02:24:09Z","timestamp":1793931849969,"version":"4.8.0"},"reference-count":26,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"Importance<\/jats:title>Patients with relapsed or refractory (r\/r) cutaneous T-cell lymphoma (CTCL) have limited treatment options. Combining agents that target complementary oncogenic pathways may enhance efficacy while maintaining tolerability.<\/jats:p><\/jats:sec>Objective<\/jats:title>To evaluate the safety and efficacy of linperlisib, a PI3K\u03b4 inhibitor, combined with chidamide, a histone deacetylase inhibitor, in patients with r\/r CTCL.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This prospective, single-arm, phase 1 nonrandomized clinical trial with a 3\u2009+\u20093 dose-escalation phase followed by dose expansion was conducted at a tertiary referral hospital in China from May 1, 2023, to March 6, 2025, with a median follow-up of 8.9 months (range, 1-21 months). It included patients with histologically confirmed advanced CTCL. All had an Eastern Cooperative Oncology Group performance status of 0 to 2 and received a median (range) of 3 (1-7) prior systemic therapies. Patients were enrolled consecutively based on eligibility.<\/jats:p><\/jats:sec>Interventions<\/jats:title>Oral linperlisib administered once daily in escalating doses (40 mg, 60 mg, or 80 mg) plus chidamide, 20 mg, twice weekly. Treatment continued until progression, unacceptable toxic effects, or withdrawal.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Primary outcomes were dose-limiting toxic effects, maximum tolerated dose, and objective response rate. Secondary outcomes included safety, progression-free survival, and disease control rate.<\/jats:p><\/jats:sec>Results<\/jats:title>Of 22 patients (19 [86.4%] with mycosis fungoides, 3 [13.6%] with S\u00e9zary syndrome), 10 were female individuals (45.5%), and the median (range) age was 44 (27-71) years. No dose-limiting toxic effects were observed. The recommended phase 2 dose of linperlisib was 80 mg. The most common treatment-related adverse events were nausea (8 [36.4%]), pruritus (7 [31.8%]), and skin rash (6 [27.3%]), mostly grade 1 to 2. Grade 3 adverse events occurred in 5 patients (22.7%); no grade 4 to 5 events were reported. The objective response rate was 59.1% (13 of 22; 95% CI, 38.7%-76.7%), including 2 complete responses and 11 partial responses. The disease control rate was 86.4% (19 of 22), and the median progression-free survival was 5.4 months.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>This nonrandomized clinical trial found that plus chidamide showed a manageable safety profile and promising activity in r\/r CTCL. This all-oral combination may represent a new therapeutic option for advanced CTCL, particularly in mycosis fungoides.<\/jats:p><\/jats:sec>Trial Registration<\/jats:title>ClinicalTrials.gov Identifier: NCT06037239<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamadermatol.2025.1926","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T11:00:33Z","timestamp":1751454033000},"page":"923","source":"Crossref","is-referenced-by-count":11,"title":["Linperlisib Plus Chidamide in Relapsed or Refractory Cutaneous T-Cell Lymphoma"],"prefix":"10.1001","volume":"161","author":[{"given":"Zhiyu","family":"Pang","sequence":"first","affiliation":[{"name":"Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yupeng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"},{"name":"Tsinghua Medicine, School of Medicine, Tsinghua University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaorui","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuofan","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziqian","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyun","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"7","key":"doi250028r1","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"doi250028r2","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The international consensus classification of mature lymphoid neoplasms: a report from the Clinical Advisory Committee.","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"issue":"16","key":"doi250028r3","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1182\/blood-2018-11-881268","article-title":"The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas.","volume":"133","author":"Willemze","year":"2019","journal-title":"Blood"},{"issue":"32","key":"doi250028r4","doi-asserted-by":"publisher","first-page":"3766","DOI":"10.1200\/JCO.2015.61.7142","article-title":"Cutaneous lymphoma international consortium study of outcome in advanced stages of mycosis fungoides and S\u00e9zary syndrome: effect of specific prognostic markers on survival and development of a prognostic model.","volume":"33","author":"Scarisbrick","year":"2015","journal-title":"J Clin Oncol"},{"issue":"5","key":"doi250028r5","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.clml.2014.01.007","article-title":"Status of PI3K\/Akt\/mTOR pathway inhibitors in lymphoma.","volume":"14","author":"Westin","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"doi250028r6","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s11899-019-00540-w","article-title":"The role of PI3K inhibition in lymphoid malignancies.","volume":"14","author":"von Keudell","year":"2019","journal-title":"Curr Hematol Malig Rep"},{"issue":"6","key":"doi250028r7","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1097\/PPO.0000000000000414","article-title":"Phosphatidylinositol 3 kinase d inhibitors: present and future.","volume":"25","author":"Brown","year":"2019","journal-title":"Cancer J"},{"key":"doi250028r8","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1097\/01.HS9.0000847552.42271.7c","article-title":"P1172: duvelisib in patients with relapsed\/refractory peripheral t-cell lymphoma from the phase 2 primo trial: updated expansion phase analysis.","volume":"6","author":"Zinzani","year":"2022","journal-title":"HemaSphere"},{"issue":"1","key":"doi250028r9","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s13045-021-01140-z","article-title":"Phase 1 clinical trial of the PI3Kd inhibitor YY-20394 in patients with B-cell hematological malignancies.","volume":"14","author":"Jiang","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"20","key":"doi250028r10","doi-asserted-by":"publisher","first-page":"4593","DOI":"10.1158\/1078-0432.CCR-24-1194","article-title":"A phase Ib study of linperlisib in the treatment of patients with relapsed and\/or refractory peripheral T-cell lymphoma.","volume":"30","author":"Jin","year":"2024","journal-title":"Clin Cancer Res"},{"key":"doi250028r11","doi-asserted-by":"publisher","first-page":"4449","DOI":"10.1182\/blood-2024-209340","article-title":"A phase II clinical study exploring the safety and efficacy of the oral PI3Kd inhibitor, linperlisib, in relapsed refractory T cell lymphoma.","volume":"144","author":"Iyer","year":"2024","journal-title":"Blood"},{"issue":"1","key":"doi250028r12","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s13148-023-01531-8","article-title":"Update on histone deacetylase inhibitors in peripheral T-cell lymphoma (PTCL).","volume":"15","author":"Lu","year":"2023","journal-title":"Clin Epigenetics"},{"issue":"23","key":"doi250028r13","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1182\/blood.V126.23.1513.1513","article-title":"Phase II study of chidamide, a new subtype-selective oral histone deacetylase inhibitor, in patients with relapsed or refractory cutaneous T-cell lymphoma.","volume":"126","author":"Shi","year":"2015","journal-title":"Blood"},{"issue":"8","key":"doi250028r14","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1093\/annonc\/mdv237","article-title":"Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma.","volume":"26","author":"Shi","year":"2015","journal-title":"Ann Oncol"},{"issue":"1","key":"doi250028r15","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13045-017-0439-6","article-title":"Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China.","volume":"10","author":"Shi","year":"2017","journal-title":"J Hematol Oncol"},{"issue":"3","key":"doi250028r16","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ccell.2016.02.011","article-title":"HDAC and PI3K antagonists cooperate to inhibit growth of MYC-driven medulloblastoma.","volume":"29","author":"Pei","year":"2016","journal-title":"Cancer Cell"},{"key":"doi250028r17","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2020.105734","article-title":"Pan-HDAC inhibitor panobinostat, as a single agent or in combination with PI3K inhibitor, induces apoptosis in APL cells: an emerging approach to overcome MSC-induced resistance.","volume":"122","author":"Mosleh","year":"2020","journal-title":"Int J Biochem Cell Biol"},{"issue":"18","key":"doi250028r18","doi-asserted-by":"publisher","first-page":"4849","DOI":"10.1158\/1078-0432.CCR-14-0034","article-title":"PI3K\/mTOR inhibition markedly potentiates HDAC inhibitor activity in NHL cells through BIM- and MCL-1-dependent mechanisms in vitro and in vivo.","volume":"20","author":"Rahmani","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"5","key":"doi250028r19","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1016\/j.jtcvs.2005.06.051","article-title":"Inhibition of phosphatidylinositol 3-kinase\/Akt and histone deacetylase activity induces apoptosis in non\u2013small cell lung cancer in vitro and in vivo.","volume":"130","author":"Denlinger","year":"2005","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"12","key":"doi250028r20","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.18632\/oncotarget.1314","article-title":"Combinatorial antitumor effect of HDAC and the PI3K-Akt-mTOR pathway inhibition in a Pten deficient model of prostate cancer.","volume":"4","author":"Ellis","year":"2013","journal-title":"Oncotarget"},{"issue":"9","key":"doi250028r21","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1038\/s41591-024-03076-6","article-title":"Duvelisib plus romidepsin in relapsed\/refractory T cell lymphomas: a phase 1b\/2a trial.","volume":"30","author":"Horwitz","year":"2024","journal-title":"Nat Med"},{"issue":"3","key":"doi250028r22","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s00204-023-03440-4","article-title":"Development and safety of PI3K inhibitors in cancer.","volume":"97","author":"Yu","year":"2023","journal-title":"Arch Toxicol"},{"issue":"11","key":"doi250028r23","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1001\/jamaoncol.2022.4327","article-title":"Incidence of cutaneous adverse events with phosphoinositide 3-kinase inhibitors as adjuvant therapy in patients with cancer: a systematic review and meta-analysis.","volume":"8","author":"Jfri","year":"2022","journal-title":"JAMA Oncol"},{"issue":"7","key":"doi250028r24","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1592\/phco.24.9.856.36106","article-title":"Likelihood and mechanisms of cross-allergenicity between sulfonamide antibiotics and other drugs containing a sulfonamide functional group.","volume":"24","author":"Brackett","year":"2004","journal-title":"Pharmacotherapy"},{"issue":"8","key":"doi250028r25","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1182\/blood-2017-08-802470","article-title":"Activity of the PI3K-d,? inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma.","volume":"131","author":"Horwitz","year":"2018","journal-title":"Blood"},{"issue":"9","key":"doi250028r26","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2835832\/jamadermatology_pang_2025_oi_250028_1757438051.04353.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T15:00:45Z","timestamp":1758121245000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2835832"}},"subtitle":["A Nonrandomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2025.1926","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,1]]}}}